Skip to content

Validation and Application of a Novel Accelerated Transcranial Magnetic Stimulation Protocol for Rapid Treatment of Depression

Validation and Application of a Novel Accelerated Transcranial Magnetic Stimulation Protocol for Rapid Treatment of Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098616
Enrollment
Unknown
Registered
2025-03-11
Start date
2025-03-20
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

SNT group:Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)
rTMS:Conventional transcranial magnetic stimulation (TMS)
Healthy control group:None

Sponsors

Zhoushan second people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 60 years; 2.Meets the diagnostic criteria for Major Depressive Disorder as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3.Total score of HAMD-17 > 17 points; 4.Right-handed; 5.Score of the Chinese version of the Beck Scale for Suicide Ideation (BSI-CV) >= 6 points; 6.The patient's physical examination, medical history, vital signs, routine blood, urine, and stool tests, liver and kidney function tests, electrolyte levels, electrocardiogram (ECG), electroencephalogram (EEG), and other indicators are normal; 7.After fully understanding the safety of transcranial magnetic stimulation (TMS), the patient is willing to actively cooperate with the treatment, and informed consent is signed by both the patient and their family members;

Exclusion criteria

Exclusion criteria: 1.Age 60 years; 2.Patients with a history of serious somatic diseases and depression caused by other psychoactive substances and non-dependent substances; 3.Patients with metal or electronic devices implanted in their bodies, such as intracranial metallic foreign bodies, cochlear implants, cardiac pacemakers, and stents; 4.Patients at risk of seizures, with a history of neurological disorders, head trauma, alcohol abuse, abnormal electroencephalogram (EEG), evidence of structural abnormalities in the brain on MRI, or a family history of epilepsy; 5.Patients with acute suicidal tendencies; 6.Patients with psychotic symptoms who require adjunctive antipsychotic medication; 7.Received ECT treatment within the 2 months prior to enrollment; 8.Pregnant, breastfeeding, or planning to become pregnant during the trial; 9.Patients who refuse to sign the informed consent form;

Design outcomes

Primary

MeasureTime frame
Depression score;

Secondary

MeasureTime frame
Anxiety score;Suicidal ideation;Electrophysiological indicators;

Countries

China

Contacts

Public ContactHuanping Zhan

Zhoushan second people's Hospital

1945616459@qq.com+86 580 2620786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026